Zhuzhou Kanghuan Trading Co., Ltd. – Trademark Portfolio

Entity Type: 99

Zhuzhou Kanghuan Trading Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include ZUZOKKAHA. The owner is based in Hunan Province.

Shop S061, 2F, Zone G, Jiacheng Times Square (Building E, 1307), No. 10, Taizi Road

Qingyun Street, Lusong District, Zhuzhou City

Hunan Province 412000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ZUZOKKAHA
ZUZOKKAHA
Registered 2025

Trademark Classifications

Zhuzhou Kanghuan Trading Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Zhuzhou Kanghuan Trading Co., Ltd. have?

Zhuzhou Kanghuan Trading Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Zhuzhou Kanghuan Trading Co., Ltd. file in?

Zhuzhou Kanghuan Trading Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Zhuzhou Kanghuan Trading Co., Ltd.'s most well-known trademarks?

Zhuzhou Kanghuan Trading Co., Ltd.'s registered trademark portfolio includes well-known marks such as ZUZOKKAHA. These are among 1 currently registered trademark in the portfolio.

What is Zhuzhou Kanghuan Trading Co., Ltd.'s trademark registration success rate?

Zhuzhou Kanghuan Trading Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.